# Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)

> **NCT03296124** · — · WITHDRAWN · sponsor: **University of Florida**

## Conditions studied

- Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03296124
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-12-07
- **Primary completion:** 2020-09
- **Final completion:** 2020-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This project currently does not have any subjects enrolled due to other PI priorities.
- **Last updated:** 2018-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03296124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03296124, "Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03296124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*